PresentationDavid AmsellemPiper Sandler & Co., Research Division All right. Well, good afternoon, everyone. This is David Amsellem from the Piper Sandler Biopharma research team. I know it's a real busy day, and we're trying to all get through the heart or really the tail end of the 3Q earnings cycle. We got a lot to cover, though, with Aquestive. And I think this will be a really informative and insightful hour that we'll be spending with the Aquestive Therapeutics senior leadership team. And we really hav ...